Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      

This page is updated frequently with new Cholesterol-related patent applications.




Date/App# patent app List of recent Cholesterol-related patents
06/09/16
20160161512 
 Method and reagent for quantifying cholesterol in high density lipoprotein 3 patent thumbnailMethod and reagent for quantifying cholesterol in high density lipoprotein 3
Disclosed are a method and a reagent for quantifying hdl3 in a test sample without requiring laborious operations. The method for quantifying cholesterol in high-density lipoprotein 3 comprises reacting a test sample with one or more surfactants which react specifically with high-density lipoprotein 3, and quantifying cholesterol.
Denka Seiken Co., Ltd.


06/09/16
20160159883 
 Fibronectin based scaffold domain proteins that bind pcsk9 patent thumbnailFibronectin based scaffold domain proteins that bind pcsk9
The present invention relates to fibronectin based scaffold domain proteins that bind pcsk9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases.
Bristol-myers Squibb Company


06/09/16
20160158296 
 Lactococcus lactis strains for producing bioactive peptides having anti-hypertensive and cholesterol-lowering effects patent thumbnailLactococcus lactis strains for producing bioactive peptides having anti-hypertensive and cholesterol-lowering effects
New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentación Y Desarrollo, A.c. (ciad)


06/02/16
20160151343 
 Non-flushing niacin analogues, and methods of use thereof patent thumbnailNon-flushing niacin analogues, and methods of use thereof
One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


06/02/16
20160151338 
 Nutraceutical composition for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia patent thumbnailNutraceutical composition for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia
A nutraceutical composition is provided for the treatment of excess weight and moderate hypercholesterolemia/dysglycemia, comprising: berberine, monacolin k, 1-deoxynojirimycin (dnj).. .
Akademy Pharma S.r.l.


06/02/16
20160151318 
 Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions patent thumbnailUse of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight, cholesterol, urine protein excretion and oxidative stress or increase the level of plasma hdl in a subject..
The University Of Utah Research Foundation


05/26/16
20160144037 
 Adjuvant compositions and related methods patent thumbnailAdjuvant compositions and related methods
The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide.
Vaxliant, Llc


05/26/16
20160143963 
 Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases patent thumbnailNovel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases
The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species bifidobacterium animalis subsp.
Biopolis, S.l.


05/26/16
20160143942 
 Compositions and their use for removing cholesterol patent thumbnailCompositions and their use for removing cholesterol
The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide.
Cornell University


05/26/16
20160143837 
 Variable color transparent lip balm and preparation method thereof patent thumbnailVariable color transparent lip balm and preparation method thereof
The present invention provides a variable color transparent lip balm, consisting of following components by weight percent: 4.0 to 5.0% by weight of dibutyl lauroyl glutamide, 2.0 to 3.0% by weight of polyamide-3, 15.0 to 20.0% by weight of bis-stearyl ethylenediamine/neopentyl glycol/stearyl hydrogenated dimer dilinoleate copolymer, 46.65 to 49.60% by weight of c12-15 alkyl benzoate, 1.0 to 3.0% by weight of heptyl undecylenate, 9.0 to 11.0% by weight of c10-30 cholesterol/lanosterol esters, 10.0 to 15.0% by weight of hydrogenated c6-20 polyolefin, 1.5 to 2.5% by weight of dextrin isostearate, 0.05 to 0.1% by weight of eosin yellowish and 0 to 0.8% by weight of excipient. The transparent lip balm of the present invention has good transparency, and excellent variable color effect..
Guangzhou Sheencolor Cosmetics Co., Ltd.


05/26/16
20160143334 

Edible composition suitable for lowering serum cholesterol


The present invention relates to an edible composition comprising plant sterol ester and/or plant stanol ester and triglyceride fat usable for lowering serum ldl cholesterol. The composition further comprises oligosaccharides and sugars.
Raisio Nutrition Ltd


05/19/16
20160139160 

Cardiovascular disease risk assessment


The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers ldl and hdl subfractions, along with lp(a) provides significant improvement in predicting cvd versus standard assays that include standard risk factors.
Boston Heart Diagnostic Corporation


05/19/16
20160138025 

Oligonucleotide conjugates


The present invention relates to oligomeric compounds and conjugates thereof that target proprotein convertase subtilisin/kexin type 9 (pcsk9) pcsk9 mrna in a cell, leading to reduced expression of pcsk9. Reduction of pcsk9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders..
Roche Innovation Center Copenhagen A/s


05/19/16
20160137746 

Methods for treating high cardiovascular risk patients with hypercholesterolemia


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


05/19/16
20160137745 

Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)


The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a pcsk9 inhibitor.
Regeneron Pharmaceuticals, Inc.


05/19/16
20160136236 

Compositions and methods of altering cholesterol levels


The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmrna molecules. The present invention also relates to compositions and methods for altering cholesterol levels using polynucleotides, primary transcripts and mmrna molecules..
Moderna Therapeutics, Inc.


05/19/16
20160136217 

Composition containing composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms


The present invention relates to a composition and functional health food containing a composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms; and a method for preventing or treating menopausal symptoms by administering the composite extract. The composite extract of rehmannia glutinosa and pueraria lobata of the present invention can ameliorate weight increase, which is the representative symptom of menopausal women, and can effectively improve osteoporosis and blood cholesterol.
University-industry Cooperation Group Of Kyung Hee University


05/19/16
20160136121 

Use of cilastatin to reduce the nephrotoxicity of different compounds


Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon


05/12/16
20160129017 

Ship inhibition to combat obesity


The present invention relates to the use of ship1 inhibitors and pan-ship1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.. .
The Research Foundation For The State University New York


05/12/16
20160128967 

Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids


A composition and a method of treatment utilizing a combination of statins (or hmg-coa reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme hmg-coa reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of eicosapentaenoic acid (epa), docosapentaenoic acid (dpa) and docosahexaenoic acid (dha) in a weight ratio of epa:dha of from 5.7 to 6.3, wherein the sum of the epa, dha and dpa represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition, the compositions and method designed to stabilize vulnerable plaque while mediating omega-3 deficiencies in individuals in need thereof.. .
Pivotal Therapeutics Inc.


05/05/16
20160122387 

Angiotensin peptide and pharmaceutical compositions for disease treatment


The present invention relates to the peptide (arg0) n-angiotensin-(1-7) [(arg0) n-ang-(1-7)], where n is 1 to 10 (xaa-asp-arg-val-tyr-ile-his-pro; seq id no:1 where xaa represents 1 to 10 l-arg residues), which is produced by inserting at least one arginine amino acid at the amino terminal position of ang-(1-7), as well as pharmaceutical compositions containing this peptide and the use thereof for the treatment or prevention of diseases or disorders that are due or associated with reduced nitric oxide production. Non-limiting examples of these diseases or disorders are cardiopulmonary and liver diseases, vascular disorders, metabolic disorders, neural disorders, genito-urinary tract disorders, skeletal muscle disorders, kidney disorders, skin disorders, alopecia or tumors.
Universidade Federal De Minas Gerais - Ufmg


05/05/16
20160120963 

Bile salt hydrolase bsh1 for regulating weight gain, serum cholesterol levels, and liver triglycerides in a mammal; bacteria strains expressing bsh1 variants


A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a bsh1 enzyme of sequence id no: 1, or a functional variant thereof; a bsh1 enzyme of sequence id no: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of bsh1.. .
University College Cork, National University Of Ireland


04/28/16
20160115211 

Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions


The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of apoa-1 binding protein (apoaibp, aibp, or ai-bp), and methods for making and using them. In alternative embodiments, apoaibp-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia.
The Regents Of The University Of California


04/28/16
20160115167 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The General Hospital Corporation


04/28/16
20160115138 

Inhibitors of cholesterol ester transfer protein


The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors..
Concert Pharmaceuticals, Inc.


04/28/16
20160113874 

Novel catatonic lipids with various head groups for oligonucleotide delivery


The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with sirna, to facilitate the cellular uptake and endosomal escape, and to knockdown target mrna both in vitro and in vivo.. .
Sirna Therapeutics. Inc.


04/28/16
20160113873 

Nanocarrier therapy for treating invasive tumors


Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis.
Children's Healthcare Of Atlanta, Inc.


04/21/16
20160109469 

Method of measuring lipoprotein's capacity to accept cholesterol


Measuring the label incorporated into the complex.. .

04/21/16
20160108082 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

04/21/16
20160106750 

Compounds for the prevention and treatment of cardiovascular diseases


The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein a-i (apoa-i), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.. .

04/21/16
20160106077 

Transgenic animal expressing alzheimer's tau protein


The present invention provides transgenic non-human animals and non-human mammalian somatic and germ cells harbouring a human dna sequence encoding alzheimer's disease (ad) derived tau protein, capable of inducing ad pathology in transgenic animals. Alzheimer's tau protein is expressed on specific genetic backgrounds allowing also simulation of different human diseases including hypertension, diabetes, hyper-cholesterolemia, which are associated with neurodegeneration and are considerable risk factors for ad development.

04/14/16
20160102126 

Novel peptides involved in energy homeostasis


The expression of a mrna encoding a putative 76 amino acid, secreted protein (“enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of enho1 mrna in two mouse models of obesity, kk-ay and lepob/lepob mice.

04/14/16
20160102074 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .

04/14/16
20160101124 

Nano-liposomal aminoglycoside-thymoquinone formulations


The nano-liposomal aminoglycoside-thymoquinone formulations are suitable for administration to a mammal and include an aminoglycoside antibiotic (amikacin, gentamicin, or tobramycin) and thymoquinone (tq) encapsulated within a liposome. The liposome-encapsulated aminoglycoside-thymoquinone (tq) formulations can be administered to a subject in need thereof.

04/07/16
20160096898 

Pc33718e


The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (pcsk9). Also provided are antibodies directed to peptides, in which the antibodies bind to pcsk9.
Rinat Neuroscience Corp.


04/07/16
20160095889 

Composition and use of lactobacillus reuteri gmnl-263 in decreasing blood lipid levels


A use of a lactobacillus reuteri gmnl-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri gmnl-263 (accession no.: cctcc m 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism.
Genmont Biotech Inc.


04/07/16
20160095888 

Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders


This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain.
Aker Biomarine Antarctic As


04/07/16
20160095835 

Compositions containing omega-3 oil and uses thereof


The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.


03/31/16
20160089355 

Composition for preventing the occurrence of cardiovascular event in multiple risk patient


Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with hmg-coa ri or a cardiovascular event occurring in a multiple risk patient.. .
Mochida Pharmaceutical Co., Ltd.


03/24/16
20160084858 

Systems and methods for non-fasting ldl cholesterol assays


In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including poe-pop-poe block copolymer, a surfactant, and a reflectivity changing reactant, the poe-pop-poe block copolymers solubilizing essentially only non-ldl cholesterol analytes, the non-ldl cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample..
Polymer Technology Systems, Inc.


03/24/16
20160083425 

Proprotein convertase subtilisin kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels


This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 da.
Srx Cardio, Llc


03/24/16
20160082061 

Nutritional composition and manufacture


A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser, at least one natural supplement for weight loss, reduction of cholesterol levels, and/or increased resistance to stress, and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms.

03/24/16
20160081994 

Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects


The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an mtp inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the mtp inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the mtp inhibitor to the subject.
The Trustees Of The University Of Pennsylvania


03/24/16
20160081385 

Process


A method for reducing the amount of cholesterol and/or improving the texture and/or reducing weight loss and/or increasing the fat stability of a meat based food product comprising: a) contacting meat with a lipid acyltransferase; b) incubating the meat contacted with the lipid acyltransferase at a temperature between about 1° c. To about 70° c.; c) producing a food product from the meat; wherein step b) is conducted before, during or after step c).
Dupont Nutrition Biosciences Aps


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074419 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

03/17/16
20160074417 

Sr-bi as a predictor of human female infertility and responsiveness to treatment


Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class b type i receptor, and kits for use therein.. .
The Johns Hopkins University


03/17/16
20160074384 

Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery


Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by mns reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window.
University Of Kentucky Research Foundation


03/17/16
20160074363 

Methods for improving lipid profiles using atrasentan


The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum ldl cholesterol, relative to the subject's baseline serum ldl cholesterol.. .
Abbvie Inc.


03/10/16
20160068812 

Method for culturing skeletal muscle for tissue engineering


The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (deta); verifying deta monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the deta monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating.
University Of Central Florida Research Foundation, Inc.


03/10/16
20160067243 

Ketoconazole enantiomer in humans


Treatment of patients with the 2s,4r ketoconazole enantiomer or its pharmaceutically acceptable salts, and solvates is useful for reducing systemic inflammation and cholesterol levels and improving glycemic control.. .
Cortendo Ab (publ)


03/03/16
20160058768 

Substituted amide compounds


The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
Pfizer Inc.


02/25/16
20160054305 

Method for measuring bile salt export transport and/or formation activity


A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, dna, rna. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ.
Biotranex, Llc


02/18/16
20160046633 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The U.s.a., As Represented By The Secretary, Department Of Health & Human Services


02/18/16
20160046575 

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)


Novel forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state nmr, and/or raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer's disease.. .
Warner-lambert Company Llc


02/18/16
20160045595 

Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds


A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from quillaja saponaria molina (quilq) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a quil a micelle and by an hydrophilic ester bond between a sterol oh− and cooh− or aldehyde groups in the quila micelle.
Moreinx Ab


02/11/16
20160039945 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr. In embodiments, the antigen binding proteins specifically bind pcsk9.
Amgen Inc.


02/11/16
20160039804 

Novel oxazolidinone derivative as cetp inhibitor, its preparation method, and pharmaceutical composition comprising the same


Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against cetp, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against cetp, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various cetp enzyme activity- or hdl cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease..
Dong-a St Co., Ltd.


02/11/16
20160038554 

Composition for reducing blood lipid and use thereof as healthcare dietary supplements


The present invention discloses a blood lipid-reducing composition, the active components of the composition are composed of fish oil, linseed oil, phytosterol ester or phytosterol. The composition mainly comprises components such as a-linolenic acid, epa, dha and phytosterol or phytosterol ester, can reduce serum total cholesterol (tc), triglyceride (tg) and low-density lipoprotein cholesterol (ldl-c), has an efficacy of reducing blood lipid.
Infinitus (china) Company Ltd.


02/04/16
20160032014 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Amgen Inc.


02/04/16
20160031951 

Peptides having reduced toxicity that stimulate cholesterol efflux


The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses.
The Regents Of The University Of California


02/04/16
20160031935 

Small molecule modulators of pcsk9 and methods of use thereof


A compound of formula (i): or a pharmaceutically acceptable salt, hydrate, solvate, or racemic mixture or stereoisomer thereof, and methods for preventing or treating an ldl-cholesterol-related disease or disorder using such compound(s), and kits and compositions comprising such compound(s).. .
Amorchem Holdings Inc.


02/04/16
20160030562 

Methods to enhance cancer treatment


Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (cdt) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering cdt and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies..
International Business Machines Corporation


01/28/16
20160024554 

Rapid, low-sample-volume cholesterol and triglyceride assays


Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates.
Theranos, Inc.


01/28/16
20160024173 

Non-hemolytic llo fusion proteins and methods of utilizing same


The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin o (llo) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest..
Advaxis, Inc.


01/28/16
20160024063 

Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient


The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating gpr40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs.
Hyundai Pharm Co., Ltd


01/28/16
20160022768 

Reconstituted high density lipoprotein formulation and production method thereof


A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as apoai or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/l and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75.
Csl Limited


01/28/16
20160022701 

Neuroactive steroids, compositions, and uses thereof


Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level s24(s)-hydroxycholesterol compared to a reference standard.. .
Sage Therapeutics, Inc.


01/21/16
20160015775 

Lipopeptides for use in treating liver diseases and cardiovascular diseases


The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the ntcp-mediated transport of test compound(s).
Ruprecht-karls-universitÄt Heidelberg


01/21/16
20160015673 

Method for lowering cholesterol


The present invention relates to the diagnosis, risk assessment, prevention, and treatment of senile dementia of the alzheimer's type (sdat). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum.
Phenomenome Discoveries Inc.


01/21/16
20160015050 

Vegetable oil composition containing palm mid-fraction fat and reducing plasma cholesterol


A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (pmf) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° c.
Brandeis University


01/14/16
20160010088 

Method for inhibiting tumor growth through rna-interference using liposomally associated cdc20 sirna


Liposomal compositions comprising of liposomes of guanidinylated cationic amphiphiles as the main lipid and cholesterol/1,2-dioleoyl-sn-glycero-3-phosphocholine (dopc)/aminopropyl polyethyleneglycol carbamyl-distearoylphosphatidyl-ethanolamine (dspe-peg-nh2) as co-lipids are described. These liposomal compositions containing encapsulated or electrostatically complexed therapeutic small interfering rnas (sirnas) against cdc20, a key cell cycle regulator, inhibit solid tumor growth and melanoma tumor growth on lung in c57bl/6j mice..
Council Of Scientific & Industrial Research






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5993

5076

0 - 1 - 101